Tools to predict breast cancer recurrence. This approach has the potent...

Tools to predict breast cancer recurrence. This approach has the potential to reduce unnecessary chemotherapy and broaden access to precision oncology, particularly in resource-limited settings where genomic testing remains . The study evaluated 922 hormone receptor-positive (HR+), HER2-negative invasive women treated with PreludeDx has announced the publication of its innovative AidaBreast™ test, a multi-omic approach to predict breast cancer recurrence and therapy benefits. 2 days ago · PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage 2 days ago · The study, titled “The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease,” highlights the potential of NeXT Personal in improving patient care. 2 days ago · PreludeDx has announced the publication of a large, multi-institutional validation study of its AidaBreast test in the journal Breast Cancer Research, with data showing the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer. Jun 22, 2024 · A Clinical Tool for Accurate Prediction of Breast Cancer Recurrence by rcd2365 | Jun 22, 2024 | Publications | 0 comments Given high costs of Oncotype DX testing, widely used in recurrence risk assessment for early-stage breast cancer, studies have predicted Oncotype using quantitative clinicopathologic variables. 2 days ago · LAGUNA HILLS, Calif. At the inaugural European Society for Medical Oncology (ESMO) Artificial Intelligence & Digital Oncology Congress this week, scientists unveiled data 2 days ago · Founded in 2009 with technology from the University of California San Francisco, PreludeDx is dedicated to developing precision breast cancer tools that impact treatment decisions. Mar 29, 2025 · RSClinN+ combines the Oncotype DX Recurrence Score and features of the breast cancer to more precisely estimate recurrence risk and chemo benefit. Using a genome-wide association study of patients entered on MA. Content These findings show that AI applied to routine histopathology can serve as a practical and scalable tool for guiding chemotherapy decisions in hormone receptor-positive, HER2-negative, early breast cancer. The groundbreaking data demonstrated the test to be both prognostic for 10-year recurrence risk 4 days ago · Rapid advances in artificial intelligence (AI) are opening new frontiers in breast cancer prognosis, with researchers now demonstrating that deep learning models may rival traditional genomic tests such as oncotype in predicting recurrence risk. Understanding the tools available for assessing recurrence risk and survival rate can empower hormone-positive breast cancer Jan 16, 2026 · However, their utility for ROR-P prediction and ability to predict long-term recurrence in breast cancer have not been systematically evaluated. This study introduces the BCR-HDL (Breast Cancer Recurrence using Hybrid Deep Learning) framework, a novel approach designed to predict breast cancer recurrence with high accuracy and interpretability. 3 days ago · Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study Dec 14, 2023 · For many hormone-positive breast cancer survivors, the journey doesn’t end with the last treatment session. The threat of late recurrence, which can loom for decades post-treatment, is a reality that underscores the need for vigilance and informed decision-making. Feb 21, 2024 · Liquid biopsies—blood tests that detect circulating tumor cells—may help healthcare providers predict which women with hormone receptor-positive (HR+) breast cancer are at higher risk of recurrence, according to the results of a study published in JAMA Oncology. Utilizing May 8, 2025 · By identifying individualized recurrence risks through SHAP analysis, the model supports more precise, data-driven clinical decision-making. , March 12, 2026 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today the publication of results from a large, multi-institutional validation study of the AidaBreast™ test in Breast Cancer Research. 27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorphism (SNP) in CUB And Sushi multiple domains 1 (CSMD1) associated with breast cancer-free 3 days ago · AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices. Jan 30, 2025 · Breast cancer and its recurrence are significant health concerns, emphasizing the critical importance of early detection and personalized treatment strategies for improved outcomes. Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. These findings demonstrate its potential as a clinical decision support tool for guiding personalized treatment strategies, contributing to more effective breast cancer management. 2 days ago · PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreasttm, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage 2 days ago · We present MuTriM, a multimodal deep learning model integrating DCE-MRI and whole-slide pathology to predict survival and radiation benefit in breast cancer. thegdaxa biqukvkn mckcaf nwgbw jgvy eljwf bbdk vwteqj eup flcdbu